We are encouraged by the first clinical results of C-CAR031 in advanced hepatocellular carcinoma (HCC) patients
AbelZeta
Biotechnology Research
Rockville, Maryland 2,888 followers
A global clinical-stage biopharmaceutical company
About us
AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body's own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases. AbelZeta advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies, with a pipeline comprised of CAR-T and TIL therapies.
- Website
-
https://www.abelzeta.com
External link for AbelZeta
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Rockville, Maryland
- Type
- Privately Held
- Founded
- 2009
- Specialties
- Biopharmaceutical, Biotechnology, Research & Development, Manufacturing, Cell Therapy, Innovation, Immuno-Oncology, and I & I
Locations
-
Primary
Get directions
9605 Medical Center Dr
Suite 100
Rockville, Maryland 20850, US
-
Get directions
85 Faladi Road
Building 3
Shanghai, SH 201210, CN
Employees at AbelZeta
Updates
-
Formation of Scientific Advisory Board to Support I&I https://lnkd.in/g5XMgBtS
-
AbelZeta's worldwide collaboration and license agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company, amended to include China. "The clinical data continues to support the potential of both assets to be best in disease in r/r NHL."
AbelZeta Announces Amendment to Worldwide Collaboration and License Agreement with Janssen to Include China
prnewswire.com
-
AbelZeta shares positive long-term follow-up results from clinical studies of C-CAR039 and C-CAR066 targeting B-cell non-Hodgkin lymphoma
Press Release from PR Newswire
social.prnewswire.com
-
AbelZeta Pharma Announces Agreement with AstraZeneca to Co-Develop a novel Glypican 3 (GPC3) Armored CAR-T Therapy in China https://lnkd.in/g4i9GYcb
AbelZeta Pharma Announces Agreement with AstraZeneca to Co-Develop a novel Glypican 3 (GPC3) Armored CAR-T Therapy in China
prnewswire.com
-
AbelZeta Announces Two Abstracts Accepted for Presentation at the 65th ASH Annual Meeting https://lnkd.in/gR77HEaS
AbelZeta Announces Two Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
prnewswire.com
-
CBMG Holdings Announces Name Change to AbelZeta Pharma, Inc. https://lnkd.in/gxTdsWTB
https://www.prnewswire.com/news-releases/cbmg-holdings-announces-name-change-to-abelzeta-pharma-inc-301993427.html